evogliptin + empagliflozin

Evogliptin + empagliflozin is a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus. Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by inhibiting renal glucose reabsorption, leading to increased urinary glucose excretion. The combination targets complementary mechanisms to improve glycemic control in patients with type 2 diabetes[4][8]. Clinical studies have shown that the pharmacokinetics and pharmacodynamics of each drug are not significantly altered when administered together, and the combination is well-tolerated[4][8].